#1652 Clinical characteristics and healthcare resource utilization associated with mild, moderate and severe Hyperkalemia in Spain: IBERIK+ Study
Rattachement africain : es. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background and Aims Hyperkalemia (HK) is a frequent complication in patient with chronic kidney disease (CKD) and heart failure (HF), especially among those treated with renin-angiotensin-aldosterone system inhibitors (RAASi). This study aims to explore the clinical characteristics of these patients and analyze their healthcare resource utilization (HCRU), comparing groups that developed mild, moderate, and severe HK in Spain. Method A descriptive, retrospective study conducted using the BIG-PAC database with Python technology in Spain. Patients with relevant diagnosis codes and/or treatments for HK and/or potassium values >5.0 mmol/L recorded in their medical history between January 2013-December 2020, with at least 2 years of follow-up, were included. The inclusion date was defined as the first HK event. Baseline characteristics and HCRUs were analyzed by HK severity: mild (5.0–5.4 mmol/L), moderate (5.5–5.9 mmol/L), and severe (≥6.0 mmol/L). Results A total of 7,006 patients (mean age: 66.9 ± 14.5 years; 52.0% women; mean BMI: 27.6 ± 4.8 kg/m2; mean eGFR: 68.1 ± 26.9 mL/min/1.73 m²; mean Charlson Comorbidity Index: 1.8 ± 2.0) were analyzed. Among them, 50.3%, 37.5%, and 12.2% had mild, moderate, and severe HK, respectively. The proportion of patients with a diagnostic code and/or treatment for HK increased with severity (mild: 22.3%, moderate: 36.6%, severe: 70.5%). Patients included with severe HK were older (mean age: 75.7 years vs 69.4 years moderate, 62.9 years mild), had a higher prevalence of comorbidities, including at least one of the following: CKD, Type 2 diabetes, hypertension and HF (81.8% vs. 79.5% moderate, 47.5% mild) and higher use of medications, particularly cardiovascular drugs (88.6% vs. 79.9% moderate, 60.1% mild) (Table 1). During the follow up period, patients included with severe HK had higher HCRUs (Table 2), including more primary care visits (14.6 vs. 13.4 moderate, 12.5 mild), specialist visits (4.8 vs. 3.2 moderate, 2.1 mild), emergency room visits (3.6 vs. 3.0 moderate, 2.1 mild) and higher hospitalization rates (34.6% vs. 25.3% moderate, 15.4% mild). Conclusion Our data highlight those patients with severe HK face greater clinical complexity and worse outcomes, as well as increased HCRU. These findings could underscore the critical importance of early detection to slow disease progression and improve HK management. This is particularly significant given that most patients experiencing mild to moderate HK episodes remain largely underdiagnosed and undertreated, representing a critical gap in care.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- #1652 Clinical characteristics and healthcare resource utilization associated with mild, moderate and severe Hyperkalemia in Spain: IBERIK+ Study
- Date Crossref
- 01/10/2025
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
INCLIVA Health Research Institute pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario 12 De Octubre pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario Infanta Leonor pays non établi dans la noticeÉtablissement de santé
-
Hospital Clínic de Barcelona pays non établi dans la noticeÉtablissement de santé
-
AstraZeneca (Spain) pays non établi dans la noticeEntreprise
-
Hospital Universitario Fundación Jiménez Díaz pays non établi dans la noticeÉtablissement de santé
-
Universidad Autónoma de Madrid pays non établi dans la noticeUniversité ou école supérieure
-
Clinical University Hospital pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Infanta Leonor pays non établi dans la noticeUniversité ou école supérieure
-
Barcelona University Hospital Clínic pays non établi dans la noticeUniversité ou école supérieure
-
Employee at AstraZeneca Spain pays non établi dans la noticeInstitution
-
IIS-Fundacion Jimenez Diaz UAM pays non établi dans la noticeInstitution
INCLIVA Health Research Institute, Hospital Universitario 12 De Octubre et Hospital Universitario Infanta Leonor, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.